-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 12 On August 10, the official website of NMPA showed that Qilu Pharmaceutical's esmolol hydrochloride injection passed the consistency evaluation
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
Esmolol hydrochloride injection is an ultra-short-acting selective β-receptor blocker, which can be used to reduce blood pressure during perioperative hypertension , and it can also be used to reduce the heart rate of sinus tachycardia
.
.
According to data from Meinnet.
com, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
com, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
Sales of terminal esmolol injection in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, 10 companies in the domestic market have approved the production of esmolol hydrochloride injection, including Qilu Pharmaceutical, China Resources Shuanghe, Osaikang, Lukang Pharmaceutical , Lingkang Pharmaceutical, and Baxter Medical
.
.
On June 16, 2021, Baxter Medical was approved for production of esmolol hydrochloride injections for imitation of the 3 types of applications, which was deemed to have passed the consistency evaluation
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
It is worth mentioning that, apart from Baxter Medical and Qilu Pharmaceutical, no other companies have deployed the consistency evaluation of esmolol hydrochloride injection
.
.
Up to now, Qilu Pharmaceutical has passed/deemedly passed the consistency evaluation for 84 varieties (155 product specifications)
.
.
Data source: Mi Neiwang database, NMPA
Medical Network News on August 12 On August 10, the official website of NMPA showed that Qilu Pharmaceutical's esmolol hydrochloride injection passed the consistency evaluation
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
Esmolol hydrochloride injection is an ultra-short-acting selective β-receptor blocker, which can be used to reduce blood pressure during perioperative hypertension , and it can also be used to reduce the heart rate of sinus tachycardia
.
.
According to data from Meinnet.
com, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
com, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
Sales of terminal esmolol injection in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, 10 companies in the domestic market have approved the production of esmolol hydrochloride injection, including Qilu Pharmaceutical, China Resources Shuanghe, Osaikang, Lukang Pharmaceutical , Lingkang Pharmaceutical, and Baxter Medical
.
.
On June 16, 2021, Baxter Medical was approved for production of esmolol hydrochloride injections for imitation of the 3 types of applications, which was deemed to have passed the consistency evaluation
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
It is worth mentioning that, apart from Baxter Medical and Qilu Pharmaceutical, no other companies have deployed the consistency evaluation of esmolol hydrochloride injection
.
.
Up to now, Qilu Pharmaceutical has passed/deemedly passed the consistency evaluation for 84 varieties (155 product specifications)
.
.
Data source: Mi Neiwang database, NMPA
Medical Network News on August 12 On August 10, the official website of NMPA showed that Qilu Pharmaceutical's esmolol hydrochloride injection passed the consistency evaluation
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
.
Esmolol is a beta-blocker.
In 2020, the terminal sales of public medical institutions in China will exceed 700 million yuan, a year-on-year increase of 24.
75%
.
Up to now, Qilu Pharmaceutical has been evaluated for 84 varieties
.
Esmolol hydrochloride injection is an ultra-short-acting selective β-receptor blocker, which can be used to reduce blood pressure during perioperative hypertension , and it can also be used to reduce the heart rate of sinus tachycardia
.
Hypertension hypertension hypertension.
According to data from Meinnet.
com, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
Hospital hospital hospitalcom, in recent years , the terminal sales of esmolol injection in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have continued to rise, with sales exceeding 700 million in 2020.
Yuan, a year-on-year increase of 24.
75%
.
Among them, Qilu Pharmaceutical occupies 94.
4% of the market share
.
Sales of terminal esmolol injection in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, 10 companies in the domestic market have approved the production of esmolol hydrochloride injection, including Qilu Pharmaceutical, China Resources Shuanghe, Osaikang, Lukang Pharmaceutical , Lingkang Pharmaceutical, and Baxter Medical
.
Medicine Medicine Medicine.
On June 16, 2021, Baxter Medical was approved for production of esmolol hydrochloride injections for imitation of the 3 types of applications, which was deemed to have passed the consistency evaluation
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
.
On August 10, the official website of NMPA showed that Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved
.
It is worth mentioning that, apart from Baxter Medical and Qilu Pharmaceutical, no other companies have deployed the consistency evaluation of esmolol hydrochloride injection
.
Enterprise business enterprise.
Up to now, Qilu Pharmaceutical has passed/deemedly passed the consistency evaluation for 84 varieties (155 product specifications)
.
.
Data source: Mi Neiwang database, NMPA
